. 2018 Mar 11;3(5):401–408. doi: 10.1001/jamacardio.2018.0569

Table 2. Treatment Effects of Evacetrapib Compared With Placebo Within Each Genotype of rs1967309.

Genotype	Conditional Logistic Regression^a						Conditional Logistic Regression Adjusted for Cardiovascular Risk Factors^b
	Evacetrapib (5-Component MACE) vs Placebo			Evacetrapib (3-Component MACE) vs Placebo			Evacetrapib (5-Component MACE) vs Placebo			Evacetrapib (3-Component MACE) vs Placebo
	OR (95% CI)	P Value		OR (95% CI)	P Value		OR (95% CI)	P Value		OR (95% CI)	P Value
	OR (95% CI)	Interaction^c	Trend^d	OR (95% CI)	Interaction^c	Trend^d	OR (95% CI)	Interaction^c	Trend^d	OR (95% CI)	Interaction^c	Trend^d
AA	0.88 (0.69- 1.12)	.17	.06	0.92 (0.67- 1.27)	.65	.83	0.93 (0.73- 1.19)	.71	.59	1.06 (0.77- 1.46)	.17	.12
AG	1.04 (0.90- 1.21)			1.05 (0.86- 1.28)			1.05 (0.91- 1.22)			1.08 (0.88- 1.32)
GG	1.18 (0.98- 1.41)			0.92 (0.72- 1.16)			1.02 (0.85- 1.24)			0.81 (0.63- 1.03)

Abbreviations: MACE, major adverse cardiovascular events; OR, odd ratio; SNP, single-nucleotide polymorphism.

^{^a}

Adjusted for age, sex, and top 5 principal components in an interaction model with treatment and SNP main effects and treatment-by-SNP interaction effect.

^{^b}

Adjusted for age, sex, top 5 principal components, and risk factors, including baseline apolipoprotein B, history of cerebral vascular disease, history of peripheral arterial disease, history of prior percutaneous coronary intervention, history of prior myocardial infarction, region, race/ethnicity, and smoking status in an interaction model with treatment and SNP main effects and treatment-by-SNP interaction effect.

^{^c}

P value for heterogeneity of treatment effects across the genotypes, using the likelihood ratio test with 2° of freedom.

^{^d}

Trend test performed after coding the genotypes as the number of minor alleles in the conditional logistic model and the corresponding genotype-by-treatment interaction tested.